Back to News
Market Impact: 0.2
Atom Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Lingdolinurad (ABP-671) for Chronic Kidney Disease with Hyperuricemia
Source: Business Wire
Healthcare & Biotech
Atom reported that the first patient has been dosed in its Phase 2 clinical trial of lingdolinurad (ABP-671) for chronic kidney disease with hyperuricemia. The milestone indicates the trial has begun dosing; the headline provides no efficacy results or additional trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- Bottoms Says Georgia Needs Pause on New Data Centers
- Genmab shares jump 13% on colorectal cancer drug trial results